PubMed Health⌕ Search

Biomedical subjects

Marek Jastrzebski

Publications and source records attributed to Marek Jastrzebski.

6 recordsLinked to original sources
PubMed2006

Electrophysiological study in a patient with Fabry disease and a short PQ interval.

A short PQ interval is a common finding in patients with Fabry disease. However, there have been few electrophysiological studies in Fabry disease, and it is not clear whether the short PQ interval that is present in this disease results from preexcitation or enhanced atrioventricular nodal conduction. We present a case of a 43-year-old man with syncope, sick sinus syndrome, a PQ interval of 80 ms, and palpitations. Electrophysiological study showed PA, AH, and HV intervals of 24, 32, and 34 ms, respectively, and features of enhanced atrioventricular nodal conduction. The presence of an atrioventricular accessory pathway was excluded. We conclude that the short PQ interval in Fabry disease can result from accelerated conduction in the atrioventricular node.

Adult↗
PubMed2006

Increased levels of inflammatory markers in hypertensives with target organ damage.

INTRODUCTION: Inflammatory markers have been reported to be elevated in hypertension. AIM: We compared levels of inflammatory markers between hypertensives (HT) with target organ damage (TOD) but without associated clinical conditions (ACC), n=55, HT with ACC, n=42, HT without TOD/ACC, n=22 and normotensive controls, n=41. METHODS: Serum levels of CRP, fibrinogen, TNF-alpha and anti-HSP60 antibodies were measured. Hypertensive complications were assessed on the basis of clinical history and the following investigations: M-mode echocardiography (left ventricular hypertrophy), Doppler: mitral and pulmonary vein flow and isovolumetric relaxation time (diastolic dysfunction), vascular ultrasound (common carotid artery intima-media thickness--IMT), pulse wave velocity (carotid-femoral arterial stiffness) and creatinine concentration (renal function). RESULTS: HT with TOD had higher concentrations of CRP than controls (1.71 vs 0.76 mg/l, p <0.0001); higher fibrinogen and TNF-a vs controls and also vs HT without TOD/ACC (2.80 vs 2.53 vs 2.49 g/l, p <0.0001) and (2.49 vs 2.00 vs 1.83 pg/ml, p=0.04), respectively. HT without TOD/ACC did not differ from the control group in inflammatory marker concentrations. HT with ACC did not differ from HT with TOD in inflammatory marker concentrations. There were no differences in anti-HSP60 antibody concentrations between all groups. In multiple regression analysis only IMT was influenced by inflammatory markers: fibrinogen (beta=0.2, p=0.02) and TNF-alpha, (beta=0.17, p=0.05). CONCLUSIONS: We conclude that inflammatory markers are elevated in HT with TOD and are not elevated in uncomplicated HT without TOD.

Aged↗
PubMed2005

[Massive myocardial hypertrophy in hypertrophic cardiomyopathy: a risk factor for sudden death and high defibrillation threshold during cardioverter-defibrillator implantation].

Two cases of hypertrophic cardiomyopathy with massive hypertrophy and high defibrillation threshold (DFT) are described. A 14-year-old boy, whose single risk factor for sudden death was extreme hypertrophy with maximum interventricular septum (IVS) thickness of 43 mm, survived an episode of ventricular fibrillation. During ICD implantation DFT testing showed energy requirements >30 J and the procedure was aborted. Amiodarone and verapamil treatment was discontinued and treatment with oral sotalol was instituted. After a period of amiodarone washout the procedure was repeated and DFT of 24 J was encountered. An 18-year-old female with massive hypertrophy (IVS thickness=35 mm) and other risk factors for sudden death underwent ICD implantation for primary prevention. During the procedure DFT=20 J and ICD with 30 J maximal output was implanted. An increase in DFT to more than 20 J was encountered during pre-discharge test. Lack of 10 J safety margin warranted ICD system revision and upgrade; during the second procedure DFT was 24 J and ICD with 35 J maximal output was implanted. In summary, in both cases ICDs with 35 J maximal output were successfully implanted.

Adolescent↗
PubMed2004

[New beta-blockers in the treatment of chronic ischaemic heart disease].

Beta-blockers are routinely used in all forms of ischaemic heart disease except variant angina. Recently, III generation beta-blockers were introduced into practice. New beta-blockers often have ancillary properties like vaso-dilating or antioxidant properties. Also slow-release formulas of old beta-blockers are now available. Several studies show that these new agents are more efficient when compared with old beta-blockers. Moreover, adverse effects of new beta-blockers are often less severe than in the case of older agents. Especially the influence on bronchi, peripheral arteries and lipid and glucose metabolism is less pronounced. The frequency of beta-blockers use is too low in Poland as well as in other European countries, despite overwhelming evidence that these agents improve prognosis. The results of Cracovian Program for Secondary Prevention of Ischaemic Heart Disease showed that the proportions of patients after myocardial infarction or myocardial revascularization prescribed beta-blockers are too low. One of the reasons is probably the doctors' concern about side effects of beta-blockers. Widespread use of new beta-blockers in everyday clinical practice may increase beta-blocker use in general and in this way improve prognosis of ischaemic heart disease patients in Europe.

Adrenergic beta-Antagonists↗